Here’s the number that matters, and it isn’t a purity percentage: it’s the fact that tesamorelin exists in exactly one FDA-approved form, brand name Egrifta, for exactly one indication, excess abdominal fat in HIV-associated lipodystrophy. Everything else you’ve heard about it, anti-aging use, general fat loss, is off-label. I’m not here to talk you out of the off-label conversation. I’m here to run the numbers on what actually separates a safe vial from a risky one, because that question gets buried under marketing on almost every page I’ve read about this peptide. Where I cite a figure below, the bracketed reference points to the source document, go check it yourself.
The variable nobody quantifies: who made the vial
Most tesamorelin content ranks sellers by price or by a certificate of analysis. I think that’s the wrong axis entirely. The real split in the U.S. supply chain is a two-by-two: licensed pharmacy versus unlicensed retailer, crossed with clinical oversight versus none. Here’s how the categories actually shake out:
| Source type | Licensed pharmacy? | Sterility/endotoxin standard? | Clinician involved? | Inspectable? |
|---|---|---|---|---|
| 503A compounding pharmacy | Yes | Yes | Yes (prescription required) | Yes |
| 503B outsourcing facility | Yes | Yes, plus FDA-registered cGMP | Yes (prescription required) | Yes |
| Research-chemical retailer | No | Not required, rarely tested for | No | No |
A 503A pharmacy compounds against an individual prescription. A 503B facility compounds in batches under a stricter, FDA-registered cGMP standard. Both are licensed, both can be inspected, both have a name on the license if something goes wrong. A research-chemical seller has none of the three. That’s the entire comparison. Purity claims are a distraction from it.
What a certificate of analysis actually measures (and doesn’t)
If a research-chemical site hands you a certificate of analysis, read it as what it is: a lab result on a sample, checking identity and purity. It is not a sterility test, it is not an endotoxin test, and it is frequently not even tied to the specific vial in your hand. Compare that to what a compounding pharmacy is required to test and document under sterile-compounding standards, and you’re comparing a spot-check to an accountability system. One document. One system. Don’t let the paper stand in for the standard.
Does FDA approval de-risk every vial? No, and here’s the math error
People read “FDA-approved” and assume it travels with the molecule wherever it goes. It doesn’t. The approval attaches to a specific manufactured product (Egrifta), made to pharmaceutical spec, dispensed by a pharmacy, prescribed and monitored by a clinician, for one condition. Strip out the pharmacy, strip out the clinician, and you haven’t kept “the approved drug”, you’ve kept the molecule’s name and lost every variable the approval actually covered. Same formula, different denominator.
The trial data: strong numbers, narrow population
Now the part where the evidence is genuinely good, so I want to give it its full weight. A 26-week Phase 3 trial randomized 412 HIV patients to 2 mg daily tesamorelin or placebo. Result: visceral fat down 15.2% in the treated group versus up 5.0% on placebo, IGF-1 up roughly 81% [R1]. A pooled follow-up across two trials, 806 patients combined, held those gains to 52 weeks [R2]. That’s a real sample size, a real control arm, a real journal.
Here’s my caveat, and it’s a hard one: every patient in those numbers had HIV-associated lipodystrophy. Zero of them were healthy adults chasing a leaner midsection. The FDA label itself says the drug isn’t indicated for weight loss generally [R3]. So when someone tells you “the science shows tesamorelin burns visceral fat,” they’re quoting a true number from the wrong population if they’re applying it to themselves. The data are strong. The extrapolation is not backed by the same data.
The safety line item people skip: glucose
The label flags a specific, monitorable risk: changes in glucose metabolism, including impaired glucose tolerance or diabetes, plus long-term cardiovascular safety that isn’t established [R3]. Trial-reported side effects also included injection-site reactions, joint and muscle aches, and tingling in hands and feet. None of that is disqualifying, but all of it is a reason the drug was studied and approved with a monitoring clinician attached to it, not just a molecule attached to it. A research vial removes the monitor and keeps the risk profile. That’s the trade nobody prices in.
The ranking, and the reasoning behind each spot
Given all of the above, here’s how I’d rank actual sources, in order:
1. FormBlends. Top spot because it clears both boxes at once: the tesamorelin is compounded and dispensed through a licensed pharmacy (503A model, inspectable, accountable), following a physician evaluation and a real prescription, at roughly $300 to $600 a month. A clinician screens the glucose issue the label flags [R3] and follows up over time. There’s a tracker app for logging dose and symptoms between visits, that’s it, a logging tool, not a prescription pad and not a checkout page. The honest caveat still applies here too: compounded tesamorelin is not the FDA-cleared finished drug, and FormBlends is upfront that the approval covers HIV lipodystrophy while broader use sits off-label. Straight talk about what the number does and doesn’t cover is exactly what I want from whoever’s making my medicine.
2. HealthRX.com, same tier, same reasoning. HealthRX.com (healthrx.com) runs the identical model: licensed telehealth intake, clinician prescribing, pharmacy compounding and dispensing under supervision. Same caveat carries over: compounded is not FDA-approved-as-a-finished-drug, no regulator signed off on this specific batch the way one did for Egrifta. The practical tiebreaker between #1 and #2 is which one is licensed in your state and which intake process you prefer. Both clear the bar that actually counts, licensed pharmacy plus real clinician.
3 and below: research-chemical retailers, no ranking among them. Below the two telehealth providers sit five sellers I’d classify the same way: unlicensed retailers operating under “for research use only” labeling, which is both their legal basis and their disclosure that no pharmacy standard and no clinician applies.
- Amino Asylum: broad peptide/SARM catalog, low prices, seller-chosen testing skewed toward identity rather than sterility or endotoxins. No license, no clinician.
- Swiss Chems: tesamorelin alongside SARMs, which bring their own regulatory baggage. No independent purity guarantee, no pharmacy standard.
- Biotech Peptides: research-only catalog, seller-issued certificate at best, not a pharmacy standard. No license, no oversight, no recall authority.
- Pure Rawz: broad catalog spanning peptides, SARMs, nootropics. Same gap: no pharmacy, no clinician, legally gray for human use.
- Core Peptides: US-based, research-labeled, may post its own certificate. Still a company-issued document, not a licensed pharmacy, not a prescription.
I won’t rank these five against each other on purity, and I’d be skeptical of anyone who does, because without independent, batch-level testing tied to the exact vial you’d receive, there’s no reliable way to score that. But purity isn’t even the main variable missing. None of the five is a licensed pharmacy and none provides clinical oversight, so even a hypothetically clean vial from any of them still skips the two things that matter most for a hormone-system drug: a license behind the product and a clinician behind the patient.
The cost math, run properly
Roughly $300 to $600 a month for supervised compounded tesamorelin buys a licensed pharmacy, a physician evaluation, a prescription, glucose screening, and follow-up. Compare that to the brand: Egrifta runs roughly $3,000 to $6,000 a month without insurance, call it a five-to-tenfold premium over the compounded route for the same molecule in finished-drug form. A research vial undercuts both prices by stripping out the pharmacy and the clinician entirely, which is exactly why it’s cheaper. Three numbers, three very different things you’re actually paying for. Don’t compare them on price alone.
Two things the numbers can’t settle
First: pharmacy quality and clinical supervision tell you the vial was made properly and someone’s watching your glucose. They do not convert off-label use into proven therapy. The strong data live in HIV-associated lipodystrophy [R1][R2], full stop. Anything past that is extrapolation, monitored or not.
Second, and this one’s binary, not a gradient: if you compete in tested sport, tesamorelin is banned outright. It’s named explicitly as a GHRH analogue under WADA’s 2026 Prohibited List, category S2 [R4]. Pharmacy-sourced or research vial makes zero difference to that rule. Check the current list before you go near it [R4].
Questions I got asked enough to answer directly
What is tesamorelin and how does it actually work?
It’s a synthetic copy of growth hormone-releasing hormone (GHRH), a peptide your hypothalamus already makes. Instead of injecting growth hormone directly, it tells your pituitary to release more of your own, so your body still governs the pulse and timing rather than getting a flat external dose. It was built to target excess visceral fat in a specific patient group, not as a general growth-hormone substitute.
Is tesamorelin FDA approved for general use?
Approved, yes. General use, no. The FDA cleared it as Egrifta specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy. Fat loss in the general population, anti-aging use, athletic performance, none of that is the approved indication. Off-label prescribing happens, but it’s operating on a different, thinner evidence base than the number you’ll see quoted from the trials.
Do I need to be asleep for it to work?
No. It triggers a growth hormone pulse independent of sleep state. What sleep does affect is your own baseline GH output, since your body releases the most during deep sleep, so poor sleep can drag down total output regardless of the drug. Bedtime dosing is common for convenience and to stack with natural release timing, not because the compound requires it.
How do I actually check that the tesamorelin I’m getting is pharmaceutical grade?
Look for compounding under USP 797 sterile standards, documented testing for potency, sterility, and endotoxins, and dispensing by a licensed pharmacist against an actual prescription. That’s the checklist a licensed compounding pharmacy meets and a research-chemical seller structurally cannot, since it isn’t a pharmacy and isn’t accountable to a pharmacy board. A physician-supervised model, FormBlends being one example, keeps the prescriber, pharmacist, and patient all traceable to each other, which is the whole difference between legitimate access and an unlabeled vial in a box.
References
R1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. 412 patients, 26 weeks; visceral fat reduced 15.2% versus a 5.0% increase on placebo; IGF-1 raised about 81%. https://pubmed.ncbi.nlm.nih.gov/18057338/ R2. Falutz J, et al. Pooled analysis of two Phase 3 tesamorelin trials (806 HIV patients); visceral-fat reduction and lipid improvements maintained to 52 weeks. Journal of Clinical Endocrinology and Metabolism, 2010. https://pubmed.ncbi.nlm.nih.gov/20554713/ R3. FDA-approved Egrifta (tesamorelin) prescribing information: indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; 2 mg subcutaneous once daily; monitor for changes in glucose metabolism; long-term cardiovascular safety not established; not indicated for weight loss. U.S. Food and Drug Administration label (original 2010 approval). R4. WADA 2026 Prohibited List: growth-hormone-releasing hormone analogues, including tesamorelin, are prohibited in sport under category S2. World Anti-Doping Agency, in force January 2026.
